Laura Shawver is about to join a lineup of biotech CEOs enjoying overnight fortunes, courtesy of the biotech IPO boom
Laura Shawver capped 2019 with an $88 million windfall from the sale of Synthorx to Sanofi. And she pivoted right back into the sweet spot in 2020.
Just months after the sale, the serial entrepreneur returned to the helm of a startup — taking the lead post at Silverback Therapeutics, which had just raised $78 million. Now she’s captaining a team that plans to end 2020 with a bang, upsizing their IPO offer and boosting the stock price range today as they eye a gain of $200 million—plus. The underwriters could add significantly more than that if they take their shares at the IPO price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.